Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $1.08 billion. The enterprise value is $1.22 billion.
| Market Cap | 1.08B |
| Enterprise Value | 1.22B |
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 172.64 million shares outstanding. The number of shares has increased by 19.55% in one year.
| Current Share Class | 172.64M |
| Shares Outstanding | 172.64M |
| Shares Change (YoY) | +19.55% |
| Shares Change (QoQ) | -1.36% |
| Owned by Insiders (%) | 5.09% |
| Owned by Institutions (%) | 62.53% |
| Float | 163.86M |
Valuation Ratios
The trailing PE ratio is 97.34 and the forward PE ratio is 49.25.
| PE Ratio | 97.34 |
| Forward PE | 49.25 |
| PS Ratio | 3.42 |
| Forward PS | 2.64 |
| PB Ratio | 82.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.67 |
| P/OCF Ratio | 22.20 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 25.46, with an EV/FCF ratio of 25.76.
| EV / Earnings | 101.94 |
| EV / Sales | 3.89 |
| EV / EBITDA | 25.46 |
| EV / EBIT | 34.10 |
| EV / FCF | 25.76 |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 19.87.
| Current Ratio | 2.12 |
| Quick Ratio | 1.42 |
| Debt / Equity | 19.87 |
| Debt / EBITDA | 4.61 |
| Debt / FCF | 5.44 |
| Interest Coverage | 1.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 6.34% |
| Return on Invested Capital (ROIC) | 8.88% |
| Return on Capital Employed (ROCE) | 13.13% |
| Weighted Average Cost of Capital (WACC) | 9.11% |
| Revenue Per Employee | $723,800 |
| Profits Per Employee | $27,605 |
| Employee Count | 435 |
| Asset Turnover | 0.89 |
| Inventory Turnover | 0.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.25% in the last 52 weeks. The beta is 0.90, so XERS's price volatility has been lower than the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | +36.25% |
| 50-Day Moving Average | 6.12 |
| 200-Day Moving Average | 7.08 |
| Relative Strength Index (RSI) | 52.29 |
| Average Volume (20 Days) | 1,454,466 |
Short Selling Information
The latest short interest is 12.36 million, so 7.16% of the outstanding shares have been sold short.
| Short Interest | 12.36M |
| Short Previous Month | 15.89M |
| Short % of Shares Out | 7.16% |
| Short % of Float | 7.55% |
| Short Ratio (days to cover) | 7.36 |
Income Statement
In the last 12 months, XERS had revenue of $314.85 million and earned $12.01 million in profits. Earnings per share was $0.06.
| Revenue | 314.85M |
| Gross Profit | 270.44M |
| Operating Income | 35.90M |
| Pretax Income | 12.01M |
| Net Income | 12.01M |
| EBITDA | 48.08M |
| EBIT | 35.90M |
| Earnings Per Share (EPS) | $0.06 |
Balance Sheet
The company has $111.75 million in cash and $258.55 million in debt, with a net cash position of -$146.80 million or -$0.85 per share.
| Cash & Cash Equivalents | 111.75M |
| Total Debt | 258.55M |
| Net Cash | -146.80M |
| Net Cash Per Share | -$0.85 |
| Equity (Book Value) | 13.01M |
| Book Value Per Share | 0.08 |
| Working Capital | 133.09M |
Cash Flow
In the last 12 months, operating cash flow was $48.53 million and capital expenditures -$1.01 million, giving a free cash flow of $47.52 million.
| Operating Cash Flow | 48.53M |
| Capital Expenditures | -1.01M |
| Depreciation & Amortization | 12.18M |
| Net Borrowing | n/a |
| Free Cash Flow | 47.52M |
| FCF Per Share | $0.28 |
Margins
Gross margin is 85.89%, with operating and profit margins of 11.40% and 3.81%.
| Gross Margin | 85.89% |
| Operating Margin | 11.40% |
| Pretax Margin | 3.81% |
| Profit Margin | 3.81% |
| EBITDA Margin | 15.27% |
| EBIT Margin | 11.40% |
| FCF Margin | 15.09% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.55% |
| Shareholder Yield | -19.55% |
| Earnings Yield | 1.11% |
| FCF Yield | 4.41% |
Analyst Forecast
The average price target for XERS is $11.29, which is 80.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.29 |
| Price Target Difference | 80.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 22.97% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of 0.79 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.79 |
| Piotroski F-Score | 7 |